Meningococcal Vaccines Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion
Loading…

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Meningococcal Vaccines Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxx11.4%
North Americaxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis


Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Meningococcal Vaccines Market News

  • January 2022

CanSino Biological announced that the national medical products administration of China approved the ACYW135 vaccine:

MCV4 vaccine, also known as MenhyciaTM, is the first of its kind to be produced in China. MenhyciaThM binds the carrier protein CRM197 with the common pathogenic meningococcal serogroups A, C, W135, and Y.

  • April 2018 

Pfizer announced TRUMENBA :

Pfizer reported that TRUMENBA  had been given FDA breakthrough therapy designation for its use in actively immunizing children between the ages of 10 and 9 years against invasive illness brought on by Neisseria meningitidis group B. The MenB vaccination has never before been recognized as a Breakthrough Therapy to help safeguard infants as early as one year old. Prior to receiving FDA approval as the first MenB vaccination in the USS, TRUMENBA was previously recognized as a Breakthrough Therapy in 2014 for the prevention of Meng in adolescents and young adults aged 10 to 25 years.

  • August 2021 

GSK launched ASK2BSure campaign:

This campaign was launched to encourage parents to see doctors about immunizing their kids against meningitis B.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Pfizer••• ••• ••• •••
GlaxoSmithKline••• ••• ••• •••
Sanofi SA••• ••• ••• •••
Serum institute of India••• ••• ••• •••
Walvax Biotechnology••• ••• ••• •••
Novartis••• ••• ••• •••
Biomed••• ••• ••• •••
Baxter international••• ••• ••• •••
Sun Pharmaceutical Industries••• ••• ••• •••
Mylan••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

The Meningococcal Vaccines market size is valued at US$ 5.2 billion in 2022 and is projected to reach US$ 13.1 billion till 2030 with a CAGR of 11.4% during forecast period.

Introduction of Meningococcal Vaccines

Neisseria meningitidis, a bacterium, is the source of the uncommon, severe condition known as meningococcal disease. It can result in blood infection as well as meningitis, an infection of the brain and spinal cord. Any vaccination used to stop Neisseria meningitides infection is referred to as a meningococcal vaccine, the following meningococcal strains: A, B, C, W-135, and Y. Different versions are effective against some or all these strains. For at least two years, the immunizations are between 85 and 100 percent effective. In areas where they are extensively utilized, there is a reduction in meningitis and sepsis. They are administered either subcutaneously or via injection into a muscle. The development of high-quality vaccines at reasonable prices, improved healthcare infrastructure, increasing prevalence of diseases brought on by microorganisms like Neisseria meningitidis, and increasing public awareness of meningococcal vaccination and related immunization are the prime drivers of the meningococcal vaccine market.
 

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Meningococcal Vaccines Market Analysis is witnessing significant growth in the near future.

In 2023, the Bivalent segment accounted for a notable share of the Meningococcal Vaccines Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst · Cognitive Market Research
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Meningococcal Vaccines Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Pfizer, GlaxoSmithKline, Sanofi SA, Serum institute of India, Walvax Biotechnology, Novartis, Biomed, Baxter international, Sun Pharmaceutical Industries, Mylan and others are profiled in the report.
Segments include Type, Age Group and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Meningococcal Vaccines Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).

Type Bivalent, Quadrivalent, Other
Age Group Adult and Children, Infant
Distribution Channel Public channel, Private channel
List of Competitors Pfizer, GlaxoSmithKline, Sanofi SA, Serum institute of India, Walvax Biotechnology, Novartis, Biomed, Baxter international, Sun Pharmaceutical Industries, Mylan

  • 1.1 Top Competitors Analysis

    • (Subject to Data Availability (Private Players))

      1.1.1 Global Meningococcal Vaccines Market Analysis by Key Players
    • 1.1.2 Top Players Ranking 2024
    • 1.1.3 New Product Launch Analysis
    • 1.1.4 Industry Mergers and Acquisition Analysis
  • 1.2 Company Profile (Data Subject to Availability) Sample Format

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.1 Pfizer
      • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.1.2 Business Overview
      • 1.2.1.3 Financials (Subject to data availability)
      • 1.2.1.4 R&D Investment (Subject to data availability)
      • 1.2.1.5 Product Types Specification
      • 1.2.1.6 Business Strategy
      • 1.2.1.7 Recent Developments
      • 1.2.1.8 Management Change
      • 1.2.1.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.2 GlaxoSmithKline
      • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.2.2 Business Overview
      • 1.2.2.3 Financials (Subject to data availability)
      • 1.2.2.4 R&D Investment (Subject to data availability)
      • 1.2.2.5 Product Types Specification
      • 1.2.2.6 Business Strategy
      • 1.2.2.7 Recent Developments
      • 1.2.2.8 Management Change
      • 1.2.2.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.3 Sanofi SA
      • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.3.2 Business Overview
      • 1.2.3.3 Financials (Subject to data availability)
      • 1.2.3.4 R&D Investment (Subject to data availability)
      • 1.2.3.5 Product Types Specification
      • 1.2.3.6 Business Strategy
      • 1.2.3.7 Recent Developments
      • 1.2.3.8 Management Change
      • 1.2.3.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.4 Serum institute of India
      • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.4.2 Business Overview
      • 1.2.4.3 Financials (Subject to data availability)
      • 1.2.4.4 R&D Investment (Subject to data availability)
      • 1.2.4.5 Product Types Specification
      • 1.2.4.6 Business Strategy
      • 1.2.4.7 Recent Developments
      • 1.2.4.8 Management Change
      • 1.2.4.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.5 Walvax Biotechnology
      • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.5.2 Business Overview
      • 1.2.5.3 Financials (Subject to data availability)
      • 1.2.5.4 R&D Investment (Subject to data availability)
      • 1.2.5.5 Product Types Specification
      • 1.2.5.6 Business Strategy
      • 1.2.5.7 Recent Developments
      • 1.2.5.8 Management Change
      • 1.2.5.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.6 Novartis
      • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.6.2 Business Overview
      • 1.2.6.3 Financials (Subject to data availability)
      • 1.2.6.4 R&D Investment (Subject to data availability)
      • 1.2.6.5 Product Types Specification
      • 1.2.6.6 Business Strategy
      • 1.2.6.7 Recent Developments
      • 1.2.6.8 Management Change
      • 1.2.6.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.7 Biomed
      • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.7.2 Business Overview
      • 1.2.7.3 Financials (Subject to data availability)
      • 1.2.7.4 R&D Investment (Subject to data availability)
      • 1.2.7.5 Product Types Specification
      • 1.2.7.6 Business Strategy
      • 1.2.7.7 Recent Developments
      • 1.2.7.8 Management Change
      • 1.2.7.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.8 Baxter international
      • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.8.2 Business Overview
      • 1.2.8.3 Financials (Subject to data availability)
      • 1.2.8.4 R&D Investment (Subject to data availability)
      • 1.2.8.5 Product Types Specification
      • 1.2.8.6 Business Strategy
      • 1.2.8.7 Recent Developments
      • 1.2.8.8 Management Change
      • 1.2.8.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.9 Sun Pharmaceutical Industries
      • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.9.2 Business Overview
      • 1.2.9.3 Financials (Subject to data availability)
      • 1.2.9.4 R&D Investment (Subject to data availability)
      • 1.2.9.5 Product Types Specification
      • 1.2.9.6 Business Strategy
      • 1.2.9.7 Recent Developments
      • 1.2.9.8 Management Change
      • 1.2.9.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.10 Mylan
      • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.10.2 Business Overview
      • 1.2.10.3 Financials (Subject to data availability)
      • 1.2.10.4 R&D Investment (Subject to data availability)
      • 1.2.10.5 Product Types Specification
      • 1.2.10.6 Business Strategy
      • 1.2.10.7 Recent Developments
      • 1.2.10.8 Management Change
      • 1.2.10.9 S.W.O.T Analysis

  • 2.1 Global Meningococcal Vaccines Market Analysis
  • 2.2 Global Meningococcal Vaccines Market Analysis by Region
  • 2.3 Global Meningococcal Vaccines Market Analysis by Type
  • 2.4 Global Meningococcal Vaccines Market Analysis by Age Group
  • 2.5 Global Meningococcal Vaccines Market Analysis by Distribution Channel
  • 2.6 Global Meningococcal Vaccines Market Analysis by Key Players

  • 3.1 North America Meningococcal Vaccines Market Analysis
  • 3.2 North America Meningococcal Vaccines Market Analysis by Country
  • 3.3 North America Meningococcal Vaccines Market Analysis by Type
  • 3.4 North America Meningococcal Vaccines Market Analysis by Age Group
  • 3.5 North America Meningococcal Vaccines Market Analysis by Distribution Channel
  • 3.6 North America Meningococcal Vaccines Market Analysis by Key Players

  • 4.1 Europe Meningococcal Vaccines Market Analysis
  • 4.2 Europe Meningococcal Vaccines Market Analysis by Country
  • 4.3 Europe Meningococcal Vaccines Market Analysis by Type
  • 4.4 Europe Meningococcal Vaccines Market Analysis by Age Group
  • 4.5 Europe Meningococcal Vaccines Market Analysis by Distribution Channel
  • 4.6 Europe Meningococcal Vaccines Market Analysis by Key Players

  • 5.1 Asia Pacific Meningococcal Vaccines Market Analysis
  • 5.2 Asia Pacific Meningococcal Vaccines Market Analysis by Country
  • 5.3 Asia Pacific Meningococcal Vaccines Market Analysis by Type
  • 5.4 Asia Pacific Meningococcal Vaccines Market Analysis by Age Group
  • 5.5 Asia Pacific Meningococcal Vaccines Market Analysis by Distribution Channel
  • 5.6 Asia Pacific Meningococcal Vaccines Market Analysis by Key Players

  • 6.1 South America Meningococcal Vaccines Market Analysis
  • 6.2 South America Meningococcal Vaccines Market Analysis by Country
  • 6.3 South America Meningococcal Vaccines Market Analysis by Type
  • 6.4 South America Meningococcal Vaccines Market Analysis by Age Group
  • 6.5 South America Meningococcal Vaccines Market Analysis by Distribution Channel
  • 6.6 South America Meningococcal Vaccines Market Analysis by Key Players

  • 7.1 Middle East Meningococcal Vaccines Market Analysis
  • 7.2 Middle East Meningococcal Vaccines Market Analysis by Country
  • 7.3 Middle East Meningococcal Vaccines Market Analysis by Type
  • 7.4 Middle East Meningococcal Vaccines Market Analysis by Age Group
  • 7.5 Middle East Meningococcal Vaccines Market Analysis by Distribution Channel
  • 7.6 Middle East Meningococcal Vaccines Market Analysis by Key Players

  • 8.1 Africa Meningococcal Vaccines Market Analysis
  • 8.2 Africa Meningococcal Vaccines Market Analysis by Country
  • 8.3 Africa Meningococcal Vaccines Market Analysis by Type
  • 8.4 Africa Meningococcal Vaccines Market Analysis by Age Group
  • 8.5 Africa Meningococcal Vaccines Market Analysis by Distribution Channel
  • 8.6 Africa Meningococcal Vaccines Market Analysis by Key Players

  • 9.1 Bivalent
    • 9.1.1 Global Bivalent Market
    • 9.1.2 Global Bivalent Market by Region
  • 9.2 Quadrivalent
    • 9.2.1 Global Quadrivalent Market
    • 9.2.2 Global Quadrivalent Market by Region
  • 9.3 Other
    • 9.3.1 Global Other Market
    • 9.3.2 Global Other Market by Region

  • 10.1 Adult and Children
    • 10.1.1 Global Adult and Children Market
    • 10.1.2 Global Adult and Children Market by Region
  • 10.2 Infant
    • 10.2.1 Global Infant Market
    • 10.2.2 Global Infant Market by Region

  • 11.1 Public channel
    • 11.1.1 Global Public channel Market
    • 11.1.2 Global Public channel Market by Region
  • 11.2 Private channel
    • 11.2.1 Global Private channel Market
    • 11.2.2 Global Private channel Market by Region

  • 12.1 Market Drivers
  • 12.2 Market Restraints
  • 12.3 Market Trends
  • 12.4 Market Opportunity
  • 12.5 Technological Road Map (Subject to Data Availability)
  • 12.6 Product Life Cycle (Subject to Data Availability)
  • 12.7 Customer and Buyer Behavior Analysis
    • 12.7.1 Consumer Demographics and Target Audience Assessment
    • 12.7.2 Digital Engagement, Customer Experience & Relationship Analysis
    • 12.7.3 Customer Buying Behavior & Purchase Decision Analysis
    • 12.7.4 Vendor Selection, Supplier Preferences & Future Demand Trends
    • 12.7.5 Pricing, Affordability & Value Perception Analysis
    • 12.7.6 Customer Segmentation & Demand Pattern Analysis
  • 12.8 PESTEL Analysis
    • 12.8.1 Political Factors
    • 12.8.2 Economic Factors
    • 12.8.3 Social Factors
    • 12.8.4 Technological Factors
    • 12.8.5 Legal Factors
    • 12.8.6 Environmental Factors
  • 12.9 Industrial Chain Analysis (Subject to Data Availability)
    • 12.9.1 Industry Chain Analysis
    • 12.9.2 Manufacturing Cost Analysis
    • 12.9.3 Supply Side Analysis
      • 12.9.3.1 Raw Material Analysis
      • 12.9.3.2 Raw Material Procurement Analysis
      • 12.9.3.3 Raw Material Price Trend Analysis
  • 12.10 Porter’s Five Forces Analysis
    • 12.10.1 Bargaining Power of Suppliers
    • 12.10.2 Bargaining Power of Buyers
    • 12.10.3 Threat of New Entrants
    • 12.10.4 Threat of Substitutes
    • 12.10.5 Degree of Competition
  • 12.11 Patent Analysis (Subject to Data Availability)
  • 12.12 ESG Analysis
  • 12.13 Geopolitical Outlook
    • 12.13.1 Global Power Realignment & Strategic Alliances
    • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
    • 12.13.3 International Trade Relations & Market Access Environment
    • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
    • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
    • 12.13.6 Technology Sovereignty & Digital Geopolitics
    • 12.13.7 Strategic Implications for Investment, Growth & Market Entry

  • This chapter isn't just about technology; it’s about certainty. We show you how AI is being used in leading industries so you can apply those same 'High-Speed' and 'High-Accuracy' principles to your own market strategy

    12.14 AI & Market Transformation
    • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
    • 12.14.2 AI-Driven Transformation of Industry Value Chain
    • 12.14.3 Evolution of Business Models & Revenue Streams
    • 12.14.4 AI-Driven Product, Service & Innovation Transformation
    • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

    • 14.1 Key Takeaways

    • Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

      14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

    Athenaeum AI Dashboard

    Research Framework · 70:30 Primary:Secondary

    Our Proprietary Methodology

    Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Meningococcal Vaccines Market Analysis Market analysis.

    01

    Primary Intelligence Gathering

    Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

    02

    Secondary Data Triangulation

    Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

    03

    Expert Validation Protocol

    Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

    04

    Athenaeum AI Processing

    Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

    05

    Editorial & QA Review

    Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

    Data Assurance Metrics
    Data Points Validated 10,400+
    Expert Interviews 54
    Countries Covered 39+
    Company Profiles 10+
    Forecast Accuracy (Historical) 94.2%
    Report Pages 250+
    Analytical Coverage
    Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

    To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

    Sources from the Pharma & Healthcare Industry

    How We Serve You

    The Three Pillars of End-to-End Market Research Services

    We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Meningococcal Vaccines Market Analysis market.

    Service 01

    Market Survey

    B2B B2C

    Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the meningococcal vaccines market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

    What's Included
    • Buyer intent & sentiment analysis
    • Purchase cycle mapping
    • Price sensitivity research
    • Channel preference profiling
    • Competitive perception study
    Most Requested
    Service 02

    Customized Market Data & Reports

    Custom Ready Report

    Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

    What's Included
    • Ready syndicate report (250+ pages)
    • Custom data scope & segmentation
    • Excel quantitative models
    • Board-ready PPT with key findings
    • Secure cloud portal access
    Service 03

    Strategic Consultation

    With Survey With Report

    Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

    What's Included
    • Dedicated analyst assigned to you
    • Live walkthrough of findings
    • Strategic Q&A sessions
    • Go-to-market recommendations
    • NDA-protected engagement

    Customize This Report

    Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.